Stocks and Investing Stocks and Investing
Thu, June 1, 2023

Gena Wang Upgraded (BLUE) to Buy and Increased Target to $8 on, Jun 1st, 2023


Published on 2024-10-28 04:07:56 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Increased Target from $7 to $8 on, Jun 1st, 2023.

Gena has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jason Gerberry of "B of A Securities" Maintained at Hold with Decreased Target to $6 on, Thursday, March 30th, 2023
  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $8 on, Thursday, March 30th, 2023


These are the ratings of the 3 analyists that currently disagree with Gena


  • Eric Joseph of "JP Morgan" Initiated at Buy and Held Target at $7 on, Friday, April 28th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Sell with Decreased Target to $3 on, Monday, April 3rd, 2023
  • Jack Allen of "Baird" Initiated at Buy and Held Target at $10 on, Tuesday, March 7th, 2023
Contributing Sources